Composition per 1 ml dose:
Active substances:
Lyophilisate (live attenuated):
Canine Distemper virus, strain CDV Bio 11/A - min. 103.1 TCID50*, max. 105.1 TCID50*
Canine Adenovirus Type 2, strain CAV-2 Bio 13 - min. 103.6 TCID50**, max. 105.3 TCID50*
Canine Parvovirus Type 2b, strain CPV-2b Bio 12/B - min. 104.3 TCID50*, min. 106.6 TCID50*
Canine Parainfluenza Type 2virus, strain CPiV-2 Bio 15 - min. 103.1 TCID50*, max. 105.1 TCID50*
Solvent (inactivated):
- Leptospira interrogans serogroup Icterohaemorrhagiae
serovar Icterohaemorrhagiae, strain MSLB 1089 GMT** ≥ 1:51 ALR***
- Leptospira interrogans serogroup Canicola
serovar Canicola, strain MSLB 1090 GMT** ≥ 1:51 ALR***
- Leptospira kirschneri serogroup Grippotyphosa
serovar Grippotyphosa, strain MSLB 1091 GMT** ≥ 1:40 ALR***
- Leptospira interrogans serogroup Australis
serovar Bratislava, strain MSLB 1088 GMT** ≥ 1:51 ALR***
Adjuvant:
Aluminium hydroxide (quantified as Al2O3) 1.8-2.2 mg
* Tissue culture infectious dose – 50%
** Geometric mean titre
*** Antibody micro agglutination-lytic reaction
Indications:
Active immunization of dogs from six weeks of age.
- to prevent mortality and clinical signs caused by canine distemper virus
- to prevent mortality and clinical signs caused by canine adenovirus type 1
- to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2
- to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus
- to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus
- to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava
- to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterhaemorrhagiae serovar Icterohaemorrhagiae
- to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogourp Grippotyphosa serovar Grippotyphosa
Onset of immunity:
- 3 weeks after the first vaccination for CDV, CAV, CPV,
- 3 weeks after completion of the primary course for CPiV and
- 4 weeks after completion of the primary course for Leptospira components.
Duration of immunity:
At least one year following the primary vaccination course for all components of DHPPi/L4.
Contraindications:
Do not use in case of hypersensitivity to the active substance, to the adjuvant or to any of the excipients..
Adverse reactions:
Following subcutaneous administration in dogs, a small transient swelling (up to 5 cm) may commonly be observed at the injection site, these can occasionally be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.
In rare cases gastrointestinal signs such as diarrhoea and vomiting or anorexia and decreased activity are possible.
As with any vaccine rare, occasional hypersensitivity reactions may occur. If such a reaction occurs, appropriate treatment should be administered without delay.
If you notice any serious or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)
Target species:
Dogs.
Dosage for each species, route(s) and method of administration
Subcutaneous use.
Basic vaccination scheme:
Two doses of Biocan Novel DHPPi/L4 3-4 weeks apart from 6 weeks of age.
Rabies:
If protection against Rabies is required:
First dose: Biocan Novel DHPPi/L4 from 8–9 weeks of age.
Second dose: Biocan Novel DHPPi/L4R 3–4 weeks later, but not before 12 weeks of age.
The efficacy of the rabies fraction is proven after a single dose from 12 weeks of age in laboratory studies. However, in field studies, 10 % of sero-negative dogs did not show seroconversion (>0.1 IU/ml) 3–4 weeks after single primary vaccination against rabies. Another 17 % did not show the 0.5 IU/ml rabies antibody titre required by some non-EU countries to travel in. In case of travelling to risk areas or for travel outside the EU veterinary surgeons may wish to use a two dose primary course including rabies or give an additional rabies vaccination after 12 weeks.
In case of need, dogs younger than 8 weeks can be vaccinated as safety of Biocan Novel DHPPi/L4R has been demonstrated in 6 weeks old dogs.
Revaccination scheme:
A single dose of Biocan Novel DHPPi/L4 to be given annually.
Advice on correct administration:
Reconstitute one vial of the lyophilisate aseptically using the contents of one vial of the solvent. Shake well and immediately inject the entire content of the reconstituted vial (1 ml) subcutaneously. Do not use chemically sterilised syringes or needles, as these may interfere with the effectiveness of the vaccine.
Reconstituted vaccine: pinkish or yellowish colour with slight opalescence.
